This segment focuses on the research, development, and clinical trials of Rilparencel (REACT), an autologous homologous cell admixture, for treating chronic kidney diseases. The core technology involves isolating, expanding, and delivering a patient's own kidney cells to repair and regenerate damaged kidney tissue. Research and development activities include preclinical studies, Phase I, II, and III clinical trials, and manufacturing process optimization. The therapeutic area is primarily focused on diabetic kidney disease and congenital anomalies of the kidney and urinary tract (CAKUT). The goal is to improve kidney function, slow disease progression, and reduce the need for dialysis or kidney transplantation. ProKidney's market positioning is as a pioneer in cell therapy for CKD, with a focus on personalized medicine. Future opportunities include expanding the application of Rilparencel to other kidney diseases and developing next-generation cell therapy products. Regulatory and clinical aspects involve navigating FDA approval pathways and ensuring patient safety and efficacy. Partnerships and collaborations are essential for clinical trial execution and commercialization.